Results 121 to 130 of about 1,137,782 (176)

Transforming multimorbidity care: Organizational barriers and provider behaviour in type 2 diabetes and cardiovascular disease

British Journal of Health Psychology, Volume 31, Issue 3, September 2026.
Abstract Background Healthcare professionals' behaviours are central to effective multimorbidity management yet remain underexplored in behavioural medicine. Co‐existing type 2 diabetes (T2D) and cardiovascular disease (CVD) present intertwined behavioural and biomedical challenges; however, the organizational and professional factors that shape ...
Jessica Emily Brown, Frederick Kanayo Umeh, Robyn Lotto, Reda Madroumi, Ian Jones, Amineh Rashidi, Lisa Newson   +6 more
wiley   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7802-7813, September 2026.
ABSTRACT Aims Cardiovascular‐kidney‐metabolic (CKM) syndrome has developed into a global public health crisis. Although integrated care is increasingly used to treat patients with CKM, current health economic models fail to capture the value of considering the CKM syndrome as a unified condition.
Volker Foos, Jieling Chen, Phil McEwan, Marc Evans, Pardeep S. Jhund, Paul R. Kalra, Hongtu Zhu, David C. Wheeler, Geraint Roberts, Martin R. Cowie, Andrew H. Briggs   +10 more
wiley   +1 more source

Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong

, 2008
Background: The term "cardiorenal syndrome" has generally been reserved for declining renal function in the setting of advanced congestive heart failure.
House AA, Ronco C, Haapio M
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

RE: ASK1, a new target in treating cardiorenal syndrome (CRS)

, 2023
RE: ASK1, a new target in treating cardiorenal syndrome ...
A J Edgley (13407291), Feby Savira (13069731), D J Kelly (13028308), A R Kompa (13407294), B H Wang (13363860), B M Jucker (13407270), R N Willette (13407273)   +6 more
core  

Value biomarker diagnosis and prediction of acute renal damage in patients with acute coronary syndromes without ST-segment elevation

RUDN Journal of Medicine, 2013
Aim: to study the prognostic value of biomarkers (urine neutrophil gelatinase-associated lipocalin (uNGAL), urine interleukin-18 (uIL-18), serum cystatin C (sCysC), serum N-terminal prohormone of brain natriuretic peptide (sNT-proBNP) depending on the ...
S Vladimirovna Avdoshina, S Vadimovna Villevalde, M Alekseevna Efremovtseva, Zh Davidovna Kobalava   +3 more
doaj  

A Four‐Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin‐Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8329-8336, September 2026.
ABSTRACT Introduction and Objective Treatment with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). The specific mechanism by which this happens has not yet been clarified.
Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Gian Pio Sorice, Marta Giaccari, Luigi Cappannoli, Umberto Capece, Amelia Splendore, Adriana Avolio, Lorenzo Diego Greco, Patricia Iozzo, Rossana Moroni, Alfredo Pontecorvi, Maria Lucia Calcagni, Francesco Burzotta, Domenico D'Amario, Filippo Crea, Lucia Leccisotti, Francesca Cinti   +18 more
wiley   +1 more source

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8347-8358, September 2026.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning   +5 more
wiley   +1 more source

Assessing hs-Troponin T and NT-proBNP in acute heart failure and cardiorenal syndrome: Diagnostic, prognostic, and functional interrelationships

Acta Marisiensis - Seria Medica
Background: Acute heart failure (AHF) is frequently complicated by renal dysfunction, leading to cardiorenal syndrome (CRS), and poses significant management challenges.
Alredha Redha Dawud Abd, Haddawi Krarr Haider, Ibrahim Hussein Fadil   +2 more
doaj   +1 more source

Ameliorative effects of Wiryeongtang (herbal medicine) on cardiorenal complications via modulation of inflammatory and fibrotic responses in diabetic mice

Integrative Medicine Research
Background: Diabetes causes cardiorenal complications characterized by inflammation, fibrosis, and metabolic dysfunction. Wiryeongtang (WRT), a traditional herbal formula, has shown potential in alleviating metabolic disorder-related complications.
Jung Joo Yoon, Hye Yoom Kim, Ai Lin Tai, Yun Jeong Yang, Sung Joo Park, Ho Sub Lee   +5 more
doaj   +1 more source